Table 1 Comparison of the clinical characteristics of studied 36 cases with HLA class I expression
From: Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma
| Â | HLA class I expression | P | Sig | ||||||
|---|---|---|---|---|---|---|---|---|---|
Negative | Low | High | Â | Â | |||||
| Â | N | % | N | % | N | % | Â | ||
Age group | ≤14 years | 3 | 33.3% | 6 | 66.7% | 9 | 50.0% | .473* | NS |
>14Â years | 6 | 66.7% | 3 | 33.3% | 9 | 50.0% | |||
Sex | Male | 6 | 66.7% | 3 | 33.3% | 18 | 100.0% | .0001* | HS |
Female | 3 | 33.3% | 6 | 66.7% | 0 | .0% | |||
Tumor stage at diagnosis | Localized | 3 | 33.3% | 6 | 66.7% | 18 | 100.0% | .0001* | HS |
Metastatic | 6 | 66.7% | 3 | 33.3% | 0 | .0% | |||
Tumor site | Lower femur | 3 | 33.3% | 6 | 66.7% | 12 | 66.7% | .250* | NS |
Middle femur | 3 | 33.3% | 0 | .0% | 3 | 16.7% | Â | Â | |
Upper tibia | 3 | 33.3% | 3 | 33.3% | 3 | 16.7% | Â | Â | |
Tumor necrosis | Poor response | 8 | 88.9% | 6 | 66.7% | 10 | 55.6% | .258* | NS |
Good response | 1 | 11.1% | 3 | 33.3% | 8 | 44.4% | |||
Histopathological variant | Chondroblastic | 3 | 33.3% | 6 | 66.7% | 3 | 16.7% | .0001* | HS |
Fibroblastic | 0 | .0% | 0 | .0% | 9 | 50.0% | |||
Osteoblastic | 6 | 66.7% | 0 | .0% | 6 | 33.3% | |||
Small cell | 0 | .0% | 3 | 33.3% | 0 | .0% | |||
Serum alkaline phosphatase | Mean ± SD | 592.1 | 372.6 | 482.5 | 298.9 | 324.0 | 228.8 | .078** | NS |